All News

Twenty pharmaceutical companies created a $1 billion fund to aid financially strained antibiotic development start-ups; the World Health Organization (WHO) concedes that coronavirus disease 2019 (COVID-19) can become airborne; the WHO will launch an independent review into the global pandemic response after the United States formally withdrew from the organization.

A recent analysis conducted by the Kaiser Family Foundation and The Joint United Nations Program on HIV/AIDS found donor governments spent $7.8 billion for HIV in 2019, a decrease of $165 million from the previous year. This number is similar to that spent a decade ago, despite a 25% increase of individuals now living with HIV in regions receiving the aid.

With more states reporting record numbers of new infections of coronavirus disease 2019 (COVID-19), the United States has surpassed 3 million confirmed cases; the Trump administration has notified the United Nations that it will be withdrawing from the World Health Organization (WHO); a new injectable given to patients every 2 months can protect against HIV better than the commonly used daily pill.

There are 3 key issues that, if addressed by Congress, can optimally assist medical groups and health systems dealing with financial struggles amid the pandemic. These include continued funding to the CARES Act Provider Relief Fund, reinstating the Medicare Accelerated and Advanced Payment program, and permanently lifting waivers on telehealth, said Jerry Penso, MD, MBA, president and CEO of the American Medical Group Association.

FDA has lifted a partial clinical hold on a phase 2 trial of a treatment for patients with relapsed or refractory (R/R) Hodgkin lymphoma from ADC Therapeutics. The trial of camidanlumab tesirine (Cami), an antibody drug conjugate that binds to CD25, is evaluating the safety and efficacy of the therapy and is intended to support the submission of a Biologics License Application to the FDA.

Between 2002 and 2015, data showed an increase in the percentage of intimate partner violence (IPV)–related emergency department claims paid by private insurance in the United States. This finding suggests the Affordable Care Act (ACA) may have increased women’s willingness and ability to seek medical attention for IPV-related injuries and disclose IPV as the source of the injuries, according to a study published in Women’s Health Issues.

A survey conducted among migraineurs in Genova, Italy, found that during the coronavirus disease 2019 (COVID-19) quarantine, patients experienced fewer migraine attacks and less pain but exhibited moderate levels of depression correlated to migraine burden.

Several novel tests for the coronavirus disease 2019 (COVID-19) are currently being manufactured, which aim to ameliorate the lag time between testing and results; health expert says that it is currently not possible to conduct contact tracing in Southern states amid the resurgence of COVID-19 cases; survey finds people older than 60 years were no more willing to adhere to social isolation and other preventive measures than younger people.

End-stage renal disease has long been one of the most expensive and debilitating conditions that affects Medicare beneficiaries. Not only does dialysis cost $90,000 a year—those awaiting a kidney transplant automatically qualify for Medicare—but the need to travel to a dialysis center multiple times a week disrupts employment and home life.

Increased particulate matter exposure is associated with worse dry eye metrics, after adjusting for humidity, according to a study published in JAMA Ophthalmology. The study also found that humidity is positively associated with dry eye metrics, potentially due to the fact that higher humidity increases microbial growth and subsequent particulate matter size and mass.

Self-isolation and potential exposure of the coronavirus disease 2019 (COVID-19) were spotlighted as notable issues affecting addiction management; hundreds of scientists have called for the World Health Organization (WHO) to revise recommendations on COVID-19 as they highlight the airborne properties of the virus; considering safety measures and other factors when exercising in public gyms.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo